Toggle light / dark theme

A team of researchers from the Harbin Institute of Technology along with partners at the First Affiliated Hospital of Harbin Medical University, both in China, has developed a tiny robot that can ferry cancer drugs through the blood-brain barrier (BBB) without setting off an immune reaction. In their paper published in the journal Science Robotics, the group describes their robot and tests with mice. Junsun Hwang and Hongsoo Choi, with the Daegu Gyeongbuk Institute of Science and Technology in Korea, have published a Focus piece in the same journal issue on the work done by the team in China.

For many years, medical scientists have sought ways to deliver drugs to the brain to treat health conditions such as brain cancers. Because the brain is protected by the skull, it is extremely difficult to inject them directly. Researchers have also been stymied in their efforts by the BBB—a filtering mechanism in the capillaries that supply blood to the brain and that blocks foreign substances from entering. Thus, simply injecting drugs into the bloodstream is not an option. In this new effort, the researchers used a defense cell type that naturally passes through the BBB to carry drugs to the brain.

To build their tiny robots, the researchers exposed groups of white blood cells called neutrophils to tiny bits of magnetic nanogel particles coated with fragments of E. coli material. Upon exposure, the neutrophils naturally encased the tiny robots, believing them to be nothing but E. coli bacteria. The microrobots were then injected into the bloodstream of a test mouse with a cancerous tumor. The team then applied a to the robots to direct them through the BBB, where they were not attacked, as the identified them as normal neutrophils, and into the brain and the tumor. Once there, the robots released their cancer-fighting drugs.

An Israeli company said Wednesday that it received European approval for its rapid coronavirus test and it was poised to help kickstart international travel.

The handheld SpectraLIT machine eliminates the need for complex lab equipment by shining light through samples and giving immediate results using the spectral signature.

This means that staff in airport booths who are currently tasked with collecting test samples and dispatching them to labs will simply have a machine at hand and be able to give passengers results after just 20 seconds of analysis.

A $2 million federal grant will enable Houston-based PolyVascular to launch human trials of what it hails as the first polymer-based heart valve for children.

In conjunction with the grant, Dr. Will Clifton has joined the medical device company as chief operating officer. He will oversee the grant as principal investigator, and will manage the company’s operations and R&D. Clifton is president and co-founder of Houston-based Enventure, a medical innovation incubator and education hub. He previously was senior director of medical affairs at Houston-based Procyrion, a clinical-stage medical device company.

PolyVascular’s Phase II grant came from the Small Business Innovation Research (SBIR) program, which promotes technological projects.

Dr Joan Mannick, Head of Research and Development at Life Biosciences, discusses the #geroscience approach in disease treatment and the exciting work being done at Life Biosciences.


#Ageing is the greatest risk factor for almost every chronic disease. Multiple studies have shown that ageing is a modifiable risk factor that can be targeted therapeutically.

In this week’s #HealthyLongevity #webinar session, Dr Joan Mannick, Head of Research and Development at Life Biosciences, discusses the #geroscience approach in disease treatment and the exciting work being done at Life Biosciences.

Register for the upcoming webinar sessions here: https://nus-sg.zoom.us/webinar/register/1816140491076/WN_ym1bHff2RwW1XI9jIwdXCA

#NUSMedicine #webinarseries

Disclaimer: The opinions and advice expressed in this webinar are those of the speakers and do not represent the views and opinions of the organizers and National University of Singapore or any of its subsidiaries or affiliates. The information provided in this webinar is for general information purposes only as part of a general discussion on public health. The information is not intended to be a substitute for professional medical advice, diagnoses or treatment; and cannot be relied on in place of consultation with your licensed healthcare provider.

All Rights Reserved.
All of the proceedings of this webinar, including the presentation of scientific papers, are intended for limited publication only, and all property rights in the material presented, including common-law copyright, are expressly reserved to the speaker or NUS. No statement or presentation made is to be regarded as dedicated to the public domain. Any sound reproduction, transcript or other use of the material presented at this course without the permission of the speaker or NUS is prohibited to the full extent of common-law copyright in such material.

Buck Institute researchers have discovered and are developing a novel, non-invasive biomarker test that can be used to measure and track performance of senolytics: a class of drugs that selectively eliminate senescent cells. The discovery is expected to play a major role in efforts to develop treatments that would battle a myriad of chronic age-related conditions that range from arthritis to lung disease to Alzheimer’s disease and glaucoma. This biomarker is a unique signaling lipid metabolite, normally exclusively intracellular, but is released when senescent cells are forced to die. This metabolite is detectible in blood and urine, making non-invasive testing possible. With a growing list of senolytic drugs in development, detecting this metabolite via a companion test could verify performance of senolytic candidates.

“The list of age-related diseases definitively linked to cellular keeps growing, as does the number of biotech companies racing to develop drugs to eliminate senescent ,” said Buck professor Judith Campisi, Ph.D., senior scientist on the study. “While the field has never been more promising, the lack of a simple biomarker to measure and track efficacy of these treatments has been a hindrance to progress. We are excited to bring this new biomarker to the field and look forward to it being used in the clinic.”

People into aging/longevity research probably know all of what’s here already.


Aubrey de Grey has been the leading voice for antiaging, aging reversal and aging damage repair for over twenty years. He founded the SENS non-profit (Strategies for Engineered Negligible Senescence (SENS). There have been six antiaging companies that have been directly spun out of SENS is researching the hardest problems related to fixing aging damage.

Repairing damage in five of the areas of aging are now highly active areas of biotech research.

SENS has helped fund lab work to show that mitochondrial mutations and loss of elasticity in the extracellular matrix can be repaired. SENS is now helping to pioneer combination antiaging therapies.

“Last year’s stimulus was about keeping the economy going, but these companies didn’t use these resources to retain their workers. These are companies that are polluting the environment, increasing the deadliness of the pandemic and letting go of their workers.”


Figures show 77 companies received $8.2bn under tax changes related to Covid relief and yet almost every one let workers go.

The results of this study confirm a direct link, on a molecular level, between the gut microbiome and brain function.


Summary: Consuming high levels of sugar-sweetened beverages early in life may lead to memory problems during adulthood. Researchers found, compared to rats who consumed only water, those who drank sugar-sweetened beverages had difficulties in memory recall associated with the hippocampus. The study also found a link between specific changes in gut bacteria in rats who drank sugary drinks and impaired brain function.

Source: USC

New research shows how drinking sugary beverages early in life may lead to impaired memory in adulthood.

The study, published today in Translational Psychiatry, also is the first to show how a specific change to the gut microbiome — the bacteria and other microorganisms growing in the stomach and intestines — can alter the function of a particular region of the brain.

Bipolar disorder affects millions of Americans, causing dramatic swings in mood and, in some people, additional effects such as memory problems.

While bipolar disorder is linked to many genes, each one making small contributions to the disease, scientists don’t know just how those genes ultimately give rise to the disorder’s effects.

However, in new research, scientists at the University of Wisconsin-Madison have found for the first time that disruptions to a particular protein called Akt can lead to the brain changes characteristic of bipolar disorder. The results offer a foundation for research into treating the often-overlooked cognitive impairments of bipolar disorder, such as memory loss, and add to a growing understanding of how the biochemistry of the brain affects health and disease.